{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:37Z","timestamp":1792831057154,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00535-026-02488-0","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:11:08Z","timestamp":1785409868000},"page":"1606-1619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD"],"prefix":"10.1007","volume":"61","author":[{"given":"Kohei","family":"Yasuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2917-5053","authenticated-orcid":false,"given":"Noriho","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumie","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Masuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinari","family":"Takamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"2809\u201317","key":"2488_CR1","volume":"20","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(2809\u201317):e28.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2488_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2488_CR3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Terrault NA, Tacke F, et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20:388\u201398.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2488_CR4","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/s42255-025-01318-6","volume":"7","author":"H Kim","year":"2025","unstructured":"Kim H, Nelson P, Nzabarushimana E, et al. Multi-omic analysis reveals transkingdom gut dysbiosis in metabolic dysfunction-associated steatotic liver disease. Nat Metab. 2025;7:1476\u201392.","journal-title":"Nat Metab"},{"key":"2488_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41575-025-01089-1","volume":"22","author":"HC Lau","year":"2025","unstructured":"Lau HC, Zhang X, Yu J. Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2025;22:619\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2488_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","volume":"17","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020;17:279\u201397.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2488_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2488_CR8","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.2337\/db22-0933","volume":"72","author":"S Sako","year":"2023","unstructured":"Sako S, Takeshita Y, Takayama H, et al. Trajectories of liver fibrosis and gene expression profiles in nonalcoholic fatty liver disease associated with diabetes. Diabetes. 2023;72:1297\u2013306.","journal-title":"Diabetes"},{"key":"2488_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2337\/dc09-0148","volume":"33","author":"E Hamaguchi","year":"2010","unstructured":"Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care. 2010;33:284\u20136.","journal-title":"Diabetes Care"},{"key":"2488_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679\u201390.","journal-title":"Lancet"},{"key":"2488_CR11","volume":"385","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Sejling AS, Sanyal AJ. Semaglutide or placebo for nonalcoholic steatohepatitis. Reply N Engl J Med. 2021;385:e6.","journal-title":"Reply N Engl J Med"},{"key":"2488_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the L","year":"2024","unstructured":"European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542.","journal-title":"J Hepatol"},{"key":"2488_CR13","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835.","journal-title":"Hepatology"},{"key":"2488_CR14","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K, et al. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care. 2022;45:2064\u201375.","journal-title":"Diabetes Care"},{"key":"2488_CR15","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care. 2018;41:1801\u20138.","journal-title":"Diabetes Care"},{"key":"2488_CR16","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.cmet.2022.08.003","volume":"34","author":"CK Wong","year":"2022","unstructured":"Wong CK, Yusta B, Koehler JA, et al. Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation. Cell Metab. 2022;34:1514-31 e7.","journal-title":"Cell Metab"},{"key":"2488_CR17","doi-asserted-by":"publisher","first-page":"2558071","DOI":"10.1080\/19490976.2025.2558071","volume":"17","author":"SB Glaros","year":"2025","unstructured":"Glaros SB, Mishra SP, Jain S, et al. Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study. Gut Microbes. 2025;17:2558071.","journal-title":"Gut Microbes"},{"key":"2488_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0708-x","volume":"17","author":"DM Lee","year":"2018","unstructured":"Lee DM, Battson ML, Jarrell DK, et al. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Cardiovasc Diabetol. 2018;17:62.","journal-title":"Cardiovasc Diabetol"},{"key":"2488_CR19","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","volume":"94","author":"EM Brunt","year":"1999","unstructured":"Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467\u201374.","journal-title":"Am J Gastroenterol"},{"key":"2488_CR20","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology"},{"key":"2488_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13300-020-00762-9","volume":"11","author":"Y Takeshita","year":"2020","unstructured":"Takeshita Y, Kanamori T, Tanaka T, et al. Study protocol for pleiotropic effects and safety of sodium-glucose cotransporter 2 inhibitor versus sulfonylurea in patients with type 2 diabetes and nonalcoholic fatty liver disease. Diabetes Ther. 2020;11:549\u201360.","journal-title":"Diabetes Ther"},{"key":"2488_CR22","first-page":"3163","volume":"11","author":"H Matsukawa","year":"2021","unstructured":"Matsukawa H, Iida N, Kitamura K, et al. Dysbiotic gut microbiota in pancreatic cancer patients form correlation networks with the oral microbiota and prognostic factors. Am J Cancer Res. 2021;11:3163\u201375.","journal-title":"Am J Cancer Res"},{"key":"2488_CR23","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s43018-021-00251-3","volume":"2","author":"N Iida","year":"2021","unstructured":"Iida N, Mizukoshi E, Yamashita T, et al. Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis. Nat Cancer. 2021;2:1039\u201354.","journal-title":"Nat Cancer"},{"key":"2488_CR24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/bioinformatics\/btr026","volume":"27","author":"R Schmieder","year":"2011","unstructured":"Schmieder R, Edwards R. Quality control and preprocessing of metagenomic datasets. Bioinformatics. 2011;27:863\u20134.","journal-title":"Bioinformatics"},{"key":"2488_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nmeth.f.303","volume":"7","author":"JG Caporaso","year":"2010","unstructured":"Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335\u20136.","journal-title":"Nat Methods"},{"key":"2488_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357\u20139.","journal-title":"Nat Methods"},{"key":"2488_CR27","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, et al. The sequence alignment\/map format and SAMtools. Bioinformatics. 2009;25:2078\u20139.","journal-title":"Bioinformatics"},{"key":"2488_CR28","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nmeth.2066","volume":"9","author":"N Segata","year":"2012","unstructured":"Segata N, Waldron L, Ballarini A, et al. Metagenomic microbial community profiling using unique clade-specific marker genes. Nat Methods. 2012;9:811\u20134.","journal-title":"Nat Methods"},{"key":"2488_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1009442","volume":"17","author":"H Mallick","year":"2021","unstructured":"Mallick H, Rahnavard A, McIver LJ, et al. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput Biol. 2021;17:e1009442.","journal-title":"PLoS Comput Biol"},{"key":"2488_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-6-r60","volume":"12","author":"N Segata","year":"2011","unstructured":"Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60.","journal-title":"Genome Biol"},{"key":"2488_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137.","journal-title":"OMICS"},{"key":"2488_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/bmc.1346","volume":"24","author":"K Shimbo","year":"2010","unstructured":"Shimbo K, Kubo S, Harada Y, et al. Automated precolumn derivatization system for analyzing physiological amino acids by liquid chromatography\/mass spectrometry. Biomed Chromatogr. 2010;24:683\u201391.","journal-title":"Biomed Chromatogr"},{"key":"2488_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","volume":"125","author":"Y Benjamini","year":"2001","unstructured":"Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279\u201384.","journal-title":"Behav Brain Res"},{"key":"2488_CR34","doi-asserted-by":"publisher","first-page":"1665421","DOI":"10.3389\/fphar.2025.1665421","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Xu X, Fan X, et al. Unraveling p-Cresol: from biosynthesis to biological and biochemical activities. Front Pharmacol. 2025;16:1665421.","journal-title":"Front Pharmacol"},{"key":"2488_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.freeradbiomed.2015.04.004","volume":"85","author":"M Andriamihaja","year":"2015","unstructured":"Andriamihaja M, Lan A, Beaumont M, et al. The deleterious metabolic and genotoxic effects of the bacterial metabolite p-cresol on colonic epithelial cells. Free Radic Biol Med. 2015;85:219\u201327.","journal-title":"Free Radic Biol Med"},{"key":"2488_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13060857","author":"S Zhu","year":"2021","unstructured":"Zhu S, Rong Y, Kiang TKL. Effects of p-Cresol on oxidative stress, glutathione depletion, and necrosis in heparg cells: comparisons to other uremic toxins and the role of p-Cresol glucuronide formation. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13060857.","journal-title":"Pharmaceutics"},{"key":"2488_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.tiv.2019.01.003","volume":"56","author":"KM Weigand","year":"2019","unstructured":"Weigand KM, Schirris TJJ, Houweling M, et al. Uremic solutes modulate hepatic bile acid handling and induce mitochondrial toxicity. Toxicol In Vitro. 2019;56:52\u201361.","journal-title":"Toxicol In Vitro"},{"key":"2488_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2023.100469","volume":"64","author":"R Mifflin","year":"2023","unstructured":"Mifflin R, Park JE, Lee M, et al. Microbial products linked to steatohepatitis are reduced by deletion of nuclear hormone receptor SHP in mice. J Lipid Res. 2023;64:100469.","journal-title":"J Lipid Res"},{"key":"2488_CR39","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","volume":"24","author":"L Hoyles","year":"2018","unstructured":"Hoyles L, Fernandez-Real JM, Federici M, et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med. 2018;24:1070\u201380.","journal-title":"Nat Med"},{"key":"2488_CR40","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nm.4345","volume":"23","author":"H Wu","year":"2017","unstructured":"Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23:850\u20138.","journal-title":"Nat Med"},{"key":"2488_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/nu15010248","author":"S Lim","year":"2023","unstructured":"Lim S, Sohn M, Florez JC, et al. Effects of initial combinations of gemigliptin plus metformin compared with glimepiride plus metformin on gut microbiota and glucose regulation in obese patients with type 2 diabetes: the INTESTINE study. Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15010248.","journal-title":"Nutrients"},{"key":"2488_CR42","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/s41467-017-01682-2","volume":"8","author":"Y Gu","year":"2017","unstructured":"Gu Y, Wang X, Li J, et al. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun. 2017;8:1785.","journal-title":"Nat Commun"},{"key":"2488_CR43","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1210\/clinem\/dgac210","volume":"107","author":"X Deng","year":"2022","unstructured":"Deng X, Zhang C, Wang P, et al. Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes. J Clin Endocrinol Metab. 2022;107:1888\u201396.","journal-title":"J Clin Endocrinol Metab"},{"key":"2488_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116167","volume":"223","author":"Z Jin","year":"2024","unstructured":"Jin Z, Yin R, Yuan Y, et al. Dapagliflozin ameliorates hepatic steatosis via suppressing LXRalpha-mediated synthesis of lipids and bile acids. Biochem Pharmacol. 2024;223:116167.","journal-title":"Biochem Pharmacol"},{"key":"2488_CR45","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2337\/dc15-0355","volume":"38","author":"G Ferrannini","year":"2015","unstructured":"Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1730\u20135.","journal-title":"Diabetes Care"},{"key":"2488_CR46","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.diabres.2017.11.016","volume":"135","author":"I Horie","year":"2018","unstructured":"Horie I, Abiru N, Hongo R, et al. Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment. Diabetes Res Clin Pract. 2018;135:178\u201384.","journal-title":"Diabetes Res Clin Pract"},{"key":"2488_CR47","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature12820","volume":"505","author":"LA David","year":"2014","unstructured":"David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559\u201363.","journal-title":"Nature"},{"key":"2488_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/nu10060761","author":"MH Do","year":"2018","unstructured":"Do MH, Lee E, Oh MJ, et al. High-glucose or -fructose diet cause changes of the gut microbiota and metabolic disorders in mice without body weight change. Nutrients. 2018. https:\/\/doi.org\/10.3390\/nu10060761.","journal-title":"Nutrients"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02488-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02488-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02488-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:56:59Z","timestamp":1792828619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02488-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2488"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02488-0","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"11 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was supported by research grants from Kowa Company Ltd.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}